<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02584946</url>
  </required_header>
  <id_info>
    <org_study_id>PEP-1513</org_study_id>
    <nct_id>NCT02584946</nct_id>
  </id_info>
  <brief_title>Avenanthramides and Exercise</brief_title>
  <official_title>Effect of Avenanthramides Supplement on Exercise-induced Physiological and Psychological Changes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PepsiCo Global R&amp;D</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PepsiCo Global R&amp;D</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the proposed study is to examine whether long-term dietary supplementation (8&#xD;
      weeks) of an oat flour cookie rich in avenanthramides (AVA) could enhance blood antioxidant&#xD;
      capacity and reduce blood inflammatory markers after a downhill running (DR) protocol among&#xD;
      human subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2, 2016</start_date>
  <completion_date type="Actual">July 5, 2016</completion_date>
  <primary_completion_date type="Actual">July 5, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean and SD of plasma concentrations of Creatine Kinase</measure>
    <time_frame>0-72 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean and SD of plasma concentrations of TNF-α</measure>
    <time_frame>0-72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean and SD of plasma concentrations of IL-6</measure>
    <time_frame>0-72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean and SD of plasma concentrations of ICAM-1, VCAM-1, NF-κB (P65), NRB, NF-κB binding to DNA, 4-Hydroxynenenol, F2-isoprostane</measure>
    <time_frame>0-72 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Avenanthramides</condition>
  <arm_group>
    <arm_group_label>Low-AVA oat flour cookies</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High-AVA oat flour cookies</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Avenanthramides</intervention_name>
    <description>AVAs are a group of diphenolic acids that are found only in oats (Avena sativa).</description>
    <arm_group_label>High-AVA oat flour cookies</arm_group_label>
    <arm_group_label>Low-AVA oat flour cookies</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1. Male and female non-obese subjects (18kg/M2&lt;BMI&lt;28kg/M2) (age 20-45 years) will be&#xD;
        recruited from the Twin Cities community. All participants will sign informed consent&#xD;
        approved by UMN-IRB and are willing to avoid oat consumption and rigorous physical activity&#xD;
        the day prior to and through test and to consume a low-polyphenol diet for 1 week prior to&#xD;
        the study. The foods rich in polyphenols include all berries, apples, pears, citrus fruits,&#xD;
        fruit juices, onions, chocolate, wine, coffee, tea, beans, nuts, soy products and most&#xD;
        spices&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of GI conditions that interfere with absorption;&#xD;
&#xD;
          2. Clinically significant endocrine, cardiovascular, pulmonary, renal, hepatic,&#xD;
             pancreatic, biliary or neurologic disorders;&#xD;
&#xD;
          3. Major trauma or surgery within 3 months of visit;&#xD;
&#xD;
          4. Cancer in the prior 2 years;&#xD;
&#xD;
          5. Allergic to oat products;&#xD;
&#xD;
          6. Women who are pregnant or lactating;&#xD;
&#xD;
          7. Smoking;&#xD;
&#xD;
          8. Drinking alcohol &gt;5 drinks/week;&#xD;
&#xD;
          9. Using nutraceuticals;&#xD;
&#xD;
         10. Blood pressure medication;&#xD;
&#xD;
         11. NSAID (&gt;800 mg ibuprofen/week)&#xD;
&#xD;
         12. Vitamin supplementation&#xD;
&#xD;
         13. Anticoagulants or hypoglycemic drugs&#xD;
&#xD;
         14. Oat products consumption and rigorous physical activity the day before the test and&#xD;
             consumption of a high-polyphenol diet in week prior to the test.&#xD;
&#xD;
         15. Moderate-intensity cardiorespiratory exercise training for ≥30 min•d-1 on ≥5 d•wk-1&#xD;
             for a total of ≥150 min•wk-1, vigorous-intensity cardiorespiratory exercise training&#xD;
             for ≥20 min•d-1 on ≥3 d•wk-1 (≥75 min•wk-1), or a combination of moderate- and&#xD;
             vigorous-intensity exercise to achieve a total energy expenditure of ≥500-1000&#xD;
             MET•min•wk-1&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li Li Ji, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>October 21, 2015</study_first_submitted>
  <study_first_submitted_qc>October 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2015</study_first_posted>
  <last_update_submitted>March 8, 2021</last_update_submitted>
  <last_update_submitted_qc>March 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

